ABSTRACT
INTRODUCTION
Photodynamic treatment (PDT) † is an investigative cancertreatment method. The basic principle of PDT is light acti- vation of a photosensitizer localized in the tumor. In this oxygen-dependent process, the activated photosensitizer induces production of cytotoxic singlet oxygen (1) . The specificity of the PDT effect correlates with the distribution and concentration of the photosensitizer in the tumor. Several photosensitizers cause prolonged cutaneous photosensitivity with limited tumor selectivity (2) . However, photosensitization can also be achieved with 5-aminolevulinic acid (ALA), a natural precursor in the biosynthesis of heme (3, 4) . The conversion of glycine and succinyl coenzyme A into ALA, followed by the synthesis of photoactive protoporphyrin IX (PpIX) to nonphotoactive heme are rate-limiting steps down the normal in vivo biosynthetic pathway. Exogenous ALA administered in excess overloads the natural regulatory mechanisms inducing selective accumulation of PpIX in many tumors. Animal studies have shown that systemic ALA administration leads to a rapid build-up of PpIX-related fluorescence revealing some specificity (3) . The combination of ethylenediaminetetraacetic acid (EDTA) 2% and ALA seems to enhance the intracellular PpIX concentration through Fe 2ϩ reduction in cells (5) . One study shows that the intracellular PpIX concentration in human leukemic cells can be increased when the enzyme ferrochelatase is inhibited (6) . Cells that have low intracellular iron levels, as do activated lymphocytes and Sezary cells, had increased PpIX levels after ALA incubation compared to normal lymphocytes with normal iron content (7) . The role of enzyme porphobilinogen deaminase (PBDG) is still not completely clarified. Hilf et al. (8) found no change in the PpIX levels after transfecting cells with PBDG. On the other hand, one study showed an association between the inhibition of PBDG and reduced PpIX synthesis, and subsequently the study suggested a correlation between ALA-induced PBDG activity and increased PpIX accumulation (9) . Basal cell carcinoma (BCC) is the most common dermatological malignant disease in Caucasian populations and its treatment is associated with substantial morbidity and cost. Commonly used treatments include excisional surgery, Mohs' surgery, radiation therapy, cryosurgery, curettage and electrodesiccation.
Topical ALA-based PDT, either with ALA alone or in combination with skin-penetration enhancers, has been shown to be effective in the treatment of superficial BCC with reported cure rates of 79-100% (10) (11) (12) (13) (14) . Further improvements in the cure rate of the thick nodular, ulcerative BCC have been achieved by the use of ALA-based PDT combined with superficial shaving of the lesions; i.e. simple subtotal intratumoral curettage. The recorded response rates are comparable to those of conventional therapies. Recurrence rates at 12 months after treatment with topical ALAbased PDT have been reported to be less than 5% (10) . The cosmetic outcome following PDT is a major advantage of this still-investigative therapeutic modality (10) .
Thus, both data from the literature and experience at the Norwegian Radium Hospital shows that the combination of ALA and laser light (LL) is an efficient and safe treatment of superficial BCC. However, lasers are expensive and have higher running costs. In addition, the use of a laser with relatively high power requires precautions related to vision hazard. Simpler and less-expensive broadband light (BL) sources have been introduced in ALA-based PDT. The present study was conducted to compare the efficacy and safety of these two light sources.
MATERIALS AND METHODS
The trial protocol was reviewed and approved by The Norwegian Medicines Control Authority (SLK) and the Regional Ethics Committee. The study was performed as a single center, parallel, randomized two-group study open for the treating investigator and blinded for the second.
Patients and lesions. Written informed consent was obtained from all patients. A total of 83 Caucasian patients with 245 previously untreated superficial BCC (clinical thickness less than 1 mm, diameter less than 3 cm) were included in the study. Only patients with less than six lesions were included. All lesions were verified by either histology or cytology before inclusion.
The patients were randomly allocated on the treatment day to one of the two arms in blocks of four patients. The primary investigator was provided with the randomization numbers in locked envelopes, one envelope for each patient. None of the patients were treated in both arms. Group LL comprised 41 patients (27 females and 14 males, mean age 62.4 years) with 111 lesions. Group BL comprised 42 patients (17 females and 25 males, mean age 62.0 years) with 134 lesions.
Treatment procedure. All lesions in both groups were treated with the same drugs. The lesions were pretreated with a dressing soaked in 99% dimetylsulfoxide (DMSO; Janssen Chimica, Geel, Belgium), a well-known skin-penetration enhancer, for 15 min followed by a topical application consisting of a cream made up of 20% ALA, 2% DMSO, 2% EDTA; (Merck, Darmstadt, Germany), 20% water and Unguentum Merck (Merck) at 100%. The lesions were subsequently covered with an occlusive nonsterile Tegaderm dressing (3M, St. Paul, MN). After 3 h the dressing was removed and the cream washed off before light application. The cream was prepared at the hospital pharmacy for each patient on the day of use.
Light dosimetry. The light doses refer to the time integral of the irradiance. Irradiance is defined as the light power per unit area incident on the lesion surface. The power of light incident on a cell inside a lesion depends on the fluence rate of light. The fluence rate takes into account light coming from all directions, even scattered light, and depends on the position of the cell, the irradiance at the lesion surface and the optical properties of the lesion.
Light sources. Two different light sources were used.
Laser light (LL).
Light (630 nm) delivered from a copper vapor laser pumping a dye laser (Cu15A and DL30; Oxford lasers, Oxford, UK) was applied. This laser has pulses with a frequency of 10 kHz; the power output of the laser was measured by an integrated sphere power meter (Laser Therapeutics, Buellton, CA). The irradiance at the skin surface was 120-150 mW/cm 2 and the light doses varied from 100 to 150 J/cm 2 . Mean light dose per lesion was 102 J/cm 2 and median light dose was 100 J/cm 2 . The distribution of light doses was as follows: 108 lesions-100 J/cm 2 , 2 lesions-200 J/cm 2 and 1 lesion-150 J/cm 2 . The optimum wavelength for ALA PDT is actually 635 nm ( Fig. 1 ), but for practical reasons, the laser was fixed at 630 nm due to co-committed use for PHOTOFRIN PDT.
Broadband-lamp light (BL). A broadband lamp developed in the Department of Biophysics at the Institute for Cancer Research, The
Norwegian Radium Hospital was used. The lamp is fed by a small power supply, delivering direct current to a 150 W halogen bulb giving 2 W of filtered light to yield a continuous spectrum of red light between 570-740 nm to the skin surface. The irradiance of red light at the skin surface was 100-180 mW/cm 2 and the total redlight dose varied within the range of 150-200 J/cm 2 . The mean light dose for each lesion was 192 J/cm 2 and the median light dose was 200 J/cm 2 . The distribution of light doses was: 22 lesions-150 J/ cm 2 and 112 lesions-200 J/cm 2 . In addition to the red emission the lamp emitted infrared radiation in the 1180-2700 nm region. The total irradiance at the skin surface including the infrared was 135-240 mW/cm 2 .
Calculation of the relative phototherapeutic efficiency of the LL and the BL. The phototherapeutic efficiency of a light source can be defined as the number of excitations per second of the photosensitizer. If PpIX is the only sensitizer absorbing light, the efficiency of a laser with a wavelength close to an excitation maximum of PpIX, like the 630 nm laser used in our study, is higher per Watt of light delivered than the efficiency of a BL. To determine the light dose required for treatment with the BL, the relative efficiency of the lamp (P BL ) as compared to the laser (P LL ) was calculated as follows. E LL is the fluence rate of the laser given in mW/cm 2 and E BL the fluence rate of the lamp. The spectrum of the lamp is S(), and the fluorescence excitation spectrum of PpIX, as measured in human cells, with an emission wavelength of 705 nm (the second emission peak of PpIX) is ⑀(). We then have: E BL ϭ # S() d. Furthermore, the efficiency of the laser is P LL ϭ E LL ⑀(630 nm) and that of the lamp is P BL ϭ # S() ⑀() d. Applying the lamp and excitation spectra given in Fig. 1 we find that P BL ϭ 0.43 P LL. This means that a light dose of 233 J/cm 2 from the BL is comparable to a light dose of 100 J/cm 2 from the laser. However, preliminary studies of photobleaching and cure rate for more than 20 lesions suggested that 200 J/cm 2 from the BL was more than sufficient (6). Thus, 200 J/cm 2 was selected as the maximum light dose.
Clinical evaluation. Clinical evaluations were performed by two investigators scoring properties with regard to response rate, cosmetic outcome and adverse effects. The treatment was blinded to the second investigator. The BCC were clinically evaluated before treatment, 3 and 6 months after treatment by both investigators. In addition, the treating investigator examined the lesions 1 week after treatment in order to evaluate early side effects.
Clinical responses were scored as complete (absence of disease), (16) 8 (7) 45 (47) 53 (48) 35 (37) 49 (45) partial (more than 50% reduction of tumor volume) or no response (less than 50% reduction of tumor volume). The cosmetic outcome of completely responding tumors were classified as excellent (no visible stigmata), good (slightly visible), fair (moderate discoloration) or poor (strong discoloration) of the treatment area.
Patients were asked to report pain intensity during treatment and in the follow-up period.
In a prolonged out-of-protocol follow-up, half of the patients were also followed up to 24 months. The reasons for not controlling the other patients beyond 6 months were advanced age, disability or a long travel distance to the hospital.
Statistics. Fischer's exact test was used to compare response rates, cosmetic results and frequencies of adverse events.
Power evaluation. The study was designed to give 80% probability for detecting a 15% difference in complete response between the two treatment groups at a significance level of 0.05. For all lesions evaluated by both investigators, the lowest of the two investigators' score was included.
RESULTS

Response rates and cosmetic outcome 6 months after treatment
Ninety-five (86%) lesions in group LL, and 110 lesions in group BL (82%), were evaluated as complete response by both investigators at the end of the study (6 months). Partial and no response was found in 3 (3%) and 13 (11%) lesions, respectively, in group LL, compared to 4 (3%) and 20 (15%) lesions in group BL ( Table 1) .
The cosmetic result was scored as good or excellent in 80 lesions (84%) in group LL and in 102 lesions (92%) in group BL. A fair cosmetic result was scored in 15 (16%) and 8 lesions (7%) in group LL and BL, respectively (Table 2) .
There was no statistical significant difference between the two light sources with regard to clinical response (P ϭ 0.49, 95% confidence interval [CI]: [Ϫ7%, ϩ14%]) or cosmetic results (P ϭ 0.075).
Only 3 of 111 lesions in the laser group were treated with higher light dose than 100 J/cm 2 , so the correlation between the light dose and clinical response was not meaningful. In the lamp group 22 lesions were treated with 150 J/cm 2 and 112 lesions with 200 J/cm 2 . There was no correlation between the light dose and clinical response. All lesions in both groups were superficial BCC and the light doses were not selected from any lesion characteristics or specific location. The selection of light doses was based on the former clinical experience for both groups.
Two partial-responding lesions were retreated and subsequently healed at the end of the study, but these lesions were recorded as partial-responding lesions within the study. All lesions were recorded as complete, partial or nonresponders after only one treatment session in the study. Lesions that received more than one treatment are described in the follow-up part.
Adverse events
Adverse events were registered by the treating investigator during treatment and 1 week, 3 and 6 months after treatment. Based on the questionnaires filled by the patients, 83% of the patients in group LL and 76% of those in group BL reported some discomfort during and after illumination. Itching, stinging, pain and some burning sensation were reported. During the first week after treatment 68% of the patients in group LL and 74% of those in group BL also reported some degree of discomfort (stinging, itching, pain, suppuration, headache, sensation of warmth or blushing).
No serious adverse events were reported during the 6 months follow-up period in the two treatment groups. There was no statistically significant difference in the frequencies of the adverse effect between the two treatment groups.
One year follow-up
The follow-up period prescribed in the protocol was 6 months. However, we also wanted to evaluate the incidence of recurrence in patients with complete-responding lesions. The total follow-up data are retrospective and were not statistically analyzed. Sixty-four and 35 patients were therefore evaluated in this prolonged out-of-protocol follow-up at 12 and 24 months, respectively.
At 12 months 64 patients were evaluated. In group LL 30 patients (73% of included patients) with 94 healed lesions (85% of included lesions) were evaluated 6 months after treatment. Ninety-two of these lesions were complete responders in the study, while two partially responding lesions were healed after one more treatment session at the end of the study. Two relapses (2%) were found, located on the lip and the nose. Twelve of the lesions (13%) showed a better cosmetic result compared to the 6 months evaluation.
In group BL 34 patients (86% of included patients) with 99 complete-responding lesions (79% of included lesions) 6 months after treatment were evaluated. Initially five of these lesions were non or partial responders, but were healed after a second treatment session, and the remaining 94 lesions were complete responders after primary treatment in the study. None of the lesions had relapsed in the 1 year followup. Nine lesions (9% of the evaluated lesions) showed a better cosmetic result compared to the 6 months evaluation.
Two year follow-up
At 24 months 35 patients were evaluated. In group LL 16 patients (39% of included patients in group LL) with 59 healed lesions (53% of included lesions in group LL) were evaluated. Two more lesions (nose and forehead) had recurred. In total four lesions (4%) had relapsed in group LL.
In group BL 19 patients (45% of included patients in group BL) with 64 healed lesions (53% of included lesions in group BL) were evaluated. Five lesions (forehead, chin, cheek, temple and leg) had recurred (5%).
Measurement of photobleaching during light exposure
During light exposure, PpIX is degraded due to photobleaching.
Since both photobleaching and tumor destruction are dependent on singlet-oxygen generation the rate of photobleaching can, at least as a first-order approximation, be used to estimate the therapeutic efficiency. After a certain light exposure all PpIX is degraded and further exposure may, unless one waits until new PpIX is reaccumulated in possible viable tumor cells (15) , have no therapeutic effect (16) . To determine whether this state was reached with the light doses used in the study we measured the photobleaching during light exposure on four lesions treated as described above. Two of the lesions were exposed to LL and four to BL. For each lesion, the illumination was interrupted briefly every 5-25 J/cm 2 . The interruptions were of similar length and frequency to ensure that reoxygenation played no role in the comparison. During these interruptions, a fiber-optic fluorescence probe connected to a fluorimeter (Perkin-Elmer LS-5), was used to measure the surface PpIX fluorescence at 635 nm with 407 nm excitation light. The resulting fluorescence-decay curves are shown in Fig. 2 . The fluorescence measured by the fluorimeter is the sum of autofluorescence from natural chromophores in the skin and PpIX fluorescence. The autofluorescence of healthy untreated skin was measured at sites near each lesion. The total fluorescence before light treatment was 5-7 times larger than the corresponding autofluorescence. In all six measurements of photobleaching a light dose of 50 J/cm 2 from the laser or 100 J/cm 2 from the BL bleached the fluorescence to a level less than that of the autofluorescence. This indicates that these light doses are sufficient to degrade all PpIX at the surface of the tumors.
DISCUSSION
Topical ALA-based PDT is an experimental treatment modality for superficial BCC. Such treatment has also been used for actinic keratosis and Mb Bowen with good results in several studies (14, (19) (20) (21) (22) . One study shows the biological effectiveness of a 1200 W metal halide lamp compared to a argon-pumped dye laser using PHOTOFRIN (QLT, Vancouver, Canada) with respect to inactivation of cells of a human cell line. (23) . However, these results have, to our knowledge, not been confirmed in a controlled clinical study. The present study was conducted to compare the efficacy and safety of topical ALA-based PDT with LL vs BL. The data do not reveal any statistically significant difference concerning cure rate or cosmetic outcome. Some aspects of using a lamp instead of laser in PDT have been considered (24, 25) . Certainly, problems of accurate light dosimetry with broadband illumination exist. Furthermore, unwanted infrared radiation may be present in the lamp spectrum, leading to heating effects. We measured the temperature at the skin surface during irradiation with two different systems, a thermocouple probe (M4052, Goerz Metrawatt, Germany) and an infrared sensor (Fluke 80T-IR, John Fluke Mfg. Co., Everett, Washington, USA). The temperature rose from about 34ЊC to about 37-38ЊC for laser exposure at 150 mW/cm 2 , and 39ЊC for BL exposure at 180 mW/cm 2 of red light. This is well below the temperatures inducing hyperthermic effects. In our study the light doses chosen were 102 J/cm 2 in the laser group and 192 J/cm 2 in the lamp group. The reasons for choosing these values were the calculated relative efficiency of the lamp, which was 43% of the laser, and the preliminary studies of cure rate and photobleaching. Several clinical studies using lamps as light source without a laser control group, indicate that topical ALA-based PDT with light doses up to 200 J/cm 2 can give clinical results comparable to results in our study (10, 11, (21) (22) (23) .
The results of our photobleaching experiments, and those of other investigators, indicate that the chosen light doses for both light sources are sufficient and comparable with respect to cure rate and cosmetic outcome (26) . Figure 2 indicates that all PpIX at the surface of the lesions is bleached away within a light dose of 50 J/cm 2 from the laser or 100 J/cm 2 from the lamp. One can expect that during treatment the PpIX in deeper layers of the tumors is bleached more slowly than the PpIX at the surface due to attenuation of the red excitation light. Considering the above-specified maximum tumor depth of 1 mm and the penetration depth of about 3 mm for the red light exciting the PpIX during treatment, this reduction of bleaching rate could not have been more than a factor of 0.7 (17) . Hence, the applied doses of 102 J/cm 2 for the laser and 192 J/cm 2 for the broadband lamp were probably sufficient to bleach all the PpIX distributed in the tumors. This may explain why no significant difference in the cure rate is observed after treatment with the different light sources.
Considering the calculated difference in phototherapeutic efficiency of the two light sources, one might expect to see a corresponding difference in the rate of photobleaching in Fig. 2 . However, we do not consider the data presented sufficient for an accurate comparison of the bleaching rates. The present bleaching curves are not corrected for PDTinduced changes in skin optics or bleaching of the autofluorescence, and only demonstrate that within certain light doses the fluorescence reached a baseline very close to the autofluorescence. Further measurements are required to determine possible differences in the bleaching rates for the two light sources. Photobleaching of PpIX may lead to the production of photoproducts, which are photosensitizers absorbing in the 670 nm region (27) . As opposed to the 630 nm laser, the 570-740 nm broadband lamp may have excited such photoproducts in the lesions during light exposure. However, the clinical end point in our study indicates no significant benefit from this ability to excite photoproducts.
During the 2 year follow-up, approximately 50% of the total lesions were included. A total of nine lesions relapsed, four (4%) in group LL and five (5%) in group BL, respectively.
The results of the present study show that topical ALAbased PDT with a broadband halogen light source gives cure rates and cosmetic outcome similar to those obtained with a LL source. Reduced costs, increased safety as well as the possibility of general use by dermatologists are other elements in favor of the lamp as a suitable light source in dermatological PDT.
